Amylin Options Signal 26% Gain After Bristol-Myers Bid: Real M&A

Options traders are betting potential acquirers from AstraZeneca Plc to Bristol-Myers Squibb Co. will have to spend 26 percent more than its current price to buy Amylin Pharmaceuticals Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.